Should all hypertensive dialysis patients receive a blocker of the renin-angiotensin system?

Current Hypertension Reports

Volumn 12, Issue 5, 2010, Pages 356-363

  Sinha, Arjun D ^a   Agarwal, Rajiv ^a  

^a RICHARD L ROUDEBUSH VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

ACE inhibitor; ARB; Blood pressure; Cardiovascular events; End stage renal disease; ESRD; Hemodialysis; Hypertension; Kidney; Mortality; Myocardial infarction; Peritoneal dialysis; RAAS; Renin angiotensin system; Residual renal function; Stroke; Treatment

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOSINOPRIL; IRBESARTAN; LISINOPRIL; LOSARTAN; MOEXIPRIL; PLACEBO; RAMIPRIL; SPIRONOLACTONE; TRANDOLAPRIL; VALSARTAN;

BLOOD PRESSURE REGULATION; BLOOD VESSEL COMPLIANCE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIALYSIS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG RESPONSE; HEART FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEMODIALYSIS; HUMAN; HYPERKALEMIA; HYPERTENSION; KIDNEY FUNCTION; MONOTHERAPY; OBSERVATIONAL STUDY; PERITONEAL DIALYSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERKALEMIA; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; META-ANALYSIS AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL DIALYSIS; RENIN-ANGIOTENSIN SYSTEM; STROKE; TREATMENT OUTCOME; VASCULAR RESISTANCE;

EID: 77958463933     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-010-0137-z     Document Type: Review

References (50)

1. U S Renal Data System: USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2009.
2. R Agarwal AR Nissenson D Batlle, et al. 2003 Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States Am J Med 115 291 297 10.1016/S0002-9343(03)00366-8 12967694 (Pubitemid 37088191)
3. R Agarwal AD Sinha 2009 Cardiovascular protection with antihypertensive drugs in dialysis patients: systematic review and meta-analysis Hypertension 53 860 866 1:CAS:528:DC%2BD1MXksFeisbk%3D 10.1161/HYPERTENSIONAHA.108.128116 19273737 This is an up-to-date meta-analysis of the available randomized clinical trials of antihypertensive medications in hemodialysis patients. The authors found antihypertensive therapy to be associated with a significant improvement in cardiovascular events, compared with controls. Hypertensive patients appeared to benefit more than normotensive patients
4. HJ Heerspink T Ninomiya S Zoungas, et al. 2009 Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials Lancet 373 1009 1015 10.1016/S0140-6736(09)60212-9 19249092 This is an up-to-date meta-analysis of the available randomized clinical trials of antihypertensive medications in hemodialysis and PD patients. The authors found antihypertensive therapy to be associated with a significant improvement in cardiovascular events and in all-cause mortality compared with controls
5. R Agarwal P Alborzi S Satyan RP Light 2009 Dry-weight reduction in hypertensive hemodialysis patients (DRIP): a randomized, controlled trial Hypertension 53 500 507 1:CAS:528:DC%2BD1MXhs1CntL0%3D 10.1161/HYPERTENSIONAHA. 108.125674 19153263
6. JM Lazarus C Hampers JP Merrill 1974 Hypertension in chronic renal failure. Treatment with hemodialysis and nephrectomy Arch Intern Med 133 1059 1066 1:STN:280:DyaE2c7mvVWntg%3D%3D 10.1001/archinte.133.6.1059 4597951
7. VM Campese N Mitra D Sandee 2006 Hypertension in renal parenchymal disease: Why is it so resistant to treatment? Kidney Int 69 967 973 1:CAS:528:DC%2BD28XitFGhtL4%3D 10.1038/sj.ki.5000177 16528245 (Pubitemid 43372170)
8. R Agarwal R Lewis JL Davis B Becker 2001 Lisinopril therapy for hemodialysis hypertension: hemodynamic and endocrine responses Am J Kidney Dis 38 1245 1250 1:CAS:528:DC%2BD38XisFCkuw%3D%3D 10.1053/ajkd.2001.29221 11728957
9. S Zheng V Nath DW Coyne 2007 ACE inhibitor-based, directly observed therapy for hypertension in hemodialysis patients Am J Nephrol 27 522 529 1:CAS:528:DC%2BD2sXhtVOrtbzL 10.1159/000107490 17700014 (Pubitemid 47482010)
10. R Saracho A Martin-Malo I Martinez, et al. 1998 Evaluation of the Losartan in Hemodialysis (ELHE) Study Kidney Int 68 S125 S129 1:CAS:528:DyaK1cXotVKgs70%3D 10.1046/j.1523-1755.1998.06825.x
11. E Gross M Rothstein S Dombek HI Juknis 2005 Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients Am J Kidney Dis 46 94 101 1:CAS:528:DC%2BD2MXmvVaqurk%3D 10.1053/j.ajkd.2005.03.005 15983962 (Pubitemid 40848437)
12. RT Krediet 2006 How to preserve residual renal function in patients with chronic kidney disease and on dialysis? Nephrol Dial Transplant 21 Suppl 2 ii42 ii46 10.1093/ndt/gfl137 16825260 (Pubitemid 44018944)
13. TH Jafar PC Stark CH Schmid, et al. 2003 Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis Ann Intern Med 139 244 252 1:CAS:528:DC%2BD3sXnt12kurs%3D 12965979
14. A Akbari G Knoll D Ferguson, et al. 2009 Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in peritoneal dialysis: systematic review and meta-analysis of randomized controlled trials Perit Dial Int 29 554 561 1:CAS:528:DC%2BD1MXhsVOmu7%2FN 19776050 This is an up-to-date systematic review and meta-analysis of the very few randomized clinical trials of ACE inhibitor and ARB therapy in PD patients. The pooled estimate from two trials found a significant slowing in loss of residual renal function at 1 year. Only a single study had cardiovascular events to report as an outcome, and there were no differences between the intervention and control groups
15. PK Li KM Chow TY Wong, et al. 2003 Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study Ann Intern Med 139 105 112 1:CAS:528:DC%2BD3sXmtFWrs74%3D 12859160
16. H Suzuki Y Kanno S Sugahara, et al. 2004 Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD Am J Kidney Dis 43 1056 1064 1:CAS:528:DC%2BD2cXltlGjs70%3D 10.1053/j.ajkd.2004.01. 019 15168386
17. J Blacher AP Guerin B Pannier, et al. 1999 Impact of aortic stiffness on survival in end-stage renal disease Circulation 99 2434 2439 1:STN:280:DyaK1M3lt1WhtQ%3D%3D 10318666
18. WH Huang CW Hsu YC Chen, et al. 2007 Angiotensin II receptor antagonists supplementation is associated with arterial stiffness: insight from a retrospective study in 116 peritoneal dialysis patients Ren Fail 29 843 848 1:CAS:528:DC%2BD2sXht1yntL%2FI 10.1080/08860220701573558 17994453 (Pubitemid 350125671)
19. A Ichihara M Hayashi Y Kaneshiro, et al. 2005 Low doses of losartan and trandolapril improve arterial stiffness in hemodialysis patients Am J Kidney Dis 45 866 874 1:CAS:528:DC%2BD2MXkslynsbk%3D 10.1053/j.ajkd.2005.02.022 15861352 (Pubitemid 43181046)
20. H Mitsuhashi K Tamura J Yamauchi, et al. 2009 Effect of losartan on ambulatory short-term blood pressure variability and cardiovascular remodeling in hypertensive patients on hemodialysis Atherosclerosis 207 186 190 1:CAS:528:DC%2BD1MXhtlyrtbfN 10.1016/j.atherosclerosis.2009.04.005 19423110
21. A Shigenaga K Tamura T Dejima, et al. 2009 Effects of angiotensin II type 1 receptor blocker on blood pressure variability and cardiovascular remodeling in hypertensive patients on chronic peritoneal dialysis Nephron Clin Pract 112 c31 c40 1:CAS:528:DC%2BD1MXmtFequrc%3D 10.1159/000210572 19342867
22. NC Edwards RP Steeds PM Stewart, et al. 2009 Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial J Am Coll Cardiol 54 505 512 1:CAS:528:DC%2BD1MXhtFaisLfP 10.1016/j.jacc.2009.03.066 19643310
23. H Suzuki H Nakamoto H Okada, et al. 2003 A selective angiotensin receptor antagonist, valsartan, produced regression of left ventricular hypertrophy associated with a reduction of arterial stiffness Adv Perit Dial 19 59 66 1:CAS:528:DC%2BD2MXivFKgsbc%3D 14763035
24. RN Foley PS Parfrey JD Harnett, et al. 1995 Clinical and echocardiographic disease in patients starting end-stage renal disease therapy Kidney Int 47 186 192 1:STN:280:DyaK2M3kvVKmsw%3D%3D 10.1038/ki.1995.22 7731145
25. JS Silberberg PE Barre SS Prichard AD Sniderman 1989 Impact of left ventricular hypertrophy on survival in end-stage renal disease Kidney Int 36 286 290 1:STN:280:DyaL1MzotlWgtA%3D%3D 10.1038/ki.1989.192 2528654
26. G Cannella E Paoletti R Delfino, et al. 1997 Prolonged therapy with ACE inhibitors induces a regression of left ventricular hypertrophy of dialyzed uremic patients independently from hypotensive effects Am J Kidney Dis 30 659 664 1:CAS:528:DyaK2sXntlWjsbw%3D 10.1016/S0272-6386(97)90490-X 9370181
27. E Paoletti P Cassottana D Bellino, et al. 2002 Left ventricular geometry and adverse cardiovascular events in chronic hemodialysis patients on prolonged therapy with ACE inhibitors Am J Kidney Dis 40 728 736 1:CAS:528: DC%2BD38Xotl2hsro%3D 10.1053/ajkd.2002.35680 12324907
28. DJ Tai TW Lim MT James, et al. 2010 Cardiovascular effects of angiotensin converting enzyme inhibition or angiotensin receptor blockade in hemodialysis: a meta-analysis Clin J Am Soc Nephrol 5 623 630 10.2215/CJN.07831109 20133488 This up-to-date and well-performed meta-analysis of the few available randomized clinical trials of ACE inhibitors and ARBs in hemodialysis patients found significantly improved left ventricular mass with ACE inhibitor or ARB therapy, but no significant improvement in cardiovascular events
29. S Taheri M Mortazavi S Shahidi, et al. 2009 Spironolactone in chronic hemodialysis patients improves cardiac function Saudi J Kidney Dis Transpl 20 392 397 19414940 This is a small randomized clinical trial of thrice-weekly spironolactone versus placebo in addition to ACE inhibitor or ARB therapy in hemodialysis patients with heart failure. The authors found significantly improved left ventricular mass and ejection fraction in the spironolactone group and no increase in hyperkalemia
30. B Pitt F Zannad WJ Remme, et al. 1999 The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators N Engl J Med 341 709 717 1:CAS:528:DyaK1MXmtVyrurk%3D 10.1056/NEJM199909023411001 10471456 (Pubitemid 29407370)
31. MD Flather S Yusuf L Kober, et al. 2000 Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group Lancet 355 1575 1581 1:CAS:528:DC%2BD3cXjs1GlurY%3D 10.1016/S0140-6736(00)02212-1 10821360
32. VC Lee DC Rhew M Dylan, et al. 2004 Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction Ann Intern Med 141 693 704 1:CAS:528:DC%2BD2cXhtVams7rN 15520426
33. EJ Rodrigues MJ Eisenberg L Pilote 2003 Effects of early and late administration of angiotensin-converting enzyme inhibitors on mortality after myocardial infarction Am J Med 115 473 479 1:CAS:528:DC%2BD3sXotVyjsL4%3D 10.1016/S0002-9343(03)00435-2 14563504 (Pubitemid 37237561)
34. C Wanner V Krane W Marz, et al. 2005 Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis N Engl J Med 353 238 248 1:CAS:528:DC%2BD2MXmt1Kms7s%3D 10.1056/NEJMoa043545 16034009 (Pubitemid 41058323)
35. BC Fellstrom AG Jardine RE Schmieder, et al. 2009 Rosuvastatin and cardiovascular events in patients undergoing hemodialysis N Engl J Med 360 1395 1407 1:CAS:528:DC%2BD1MXjvFCqtrY%3D 10.1056/NEJMoa0810177 19332456
36. RN Foley CA Herzog AJ Collins 2002 Blood pressure and long-term mortality in United States hemodialysis patients: USRDS Waves 3 and 4 Study Kidney Int 62 1784 1790 10.1046/j.1523-1755.2002.00636.x 12371980 (Pubitemid 35286287)
37. FC Trespalacios AJ Taylor LY Agodoa KC Abbott 2002 Incident acute coronary syndromes in chronic dialysis patients in the United States Kidney Int 62 1799 1805 10.1046/j.1523-1755.2002.00638.x 12371982 (Pubitemid 35286289)
38. B Kestenbaum DL Gillen DJ Sherrard, et al. 2002 Calcium channel blocker use and mortality among patients with end-stage renal disease Kidney Int 61 2157 2164 1:CAS:528:DC%2BD38Xks1ektrw%3D 10.1046/j.1523-1755.2002.00355.x 12028456 (Pubitemid 34539333)
39. FC Trespalacios AJ Taylor LY Agodoa, et al. 2003 Heart failure as a cause for hospitalization in chronic dialysis patients Am J Kidney Dis 41 1267 1277 10.1016/S0272-6386(03)00359-7 12776280 (Pubitemid 36637983)
40. TF Griffith BS Chua AS Allen, et al. 2003 Characteristics of treated hypertension in incident hemodialysis and peritoneal dialysis patients Am J Kidney Dis 42 1260 1269 10.1053/j.ajkd.2003.08.028 14655199 (Pubitemid 37486771)
41. KC Abbott FC Trespalacios LY Agodoa, et al. 2004 Beta-blocker use in long-term dialysis patients: association with hospitalized heart failure and mortality Arch Intern Med 164 2465 2471 1:CAS:528:DC%2BD2MXks1KntA%3D%3D 10.1001/archinte.164.22.2465 15596637 (Pubitemid 39628074)
42. A Ishani CA Herzog AJ Collins RN Foley 2004 Cardiac medications and their association with cardiovascular events in incident dialysis patients: cause or effect? Kidney Int 65 1017 1025 10.1111/j.1523-1755.2004.00473.x 14871422 (Pubitemid 38251078)
43. S Efrati R Zaidenstein V Dishy, et al. 2002 ACE inhibitors and survival of hemodialysis patients Am J Kidney Dis 40 1023 1029 1:CAS:528: DC%2BD38XptVKgurg%3D 10.1053/ajkd.2002.36340 12407648 (Pubitemid 35265483)
44. W Fang DG Oreopoulos JM Bargman 2008 Use of ACE inhibitors or angiotensin receptor blockers and survival in patients on peritoneal dialysis Nephrol Dial Transplant 23 3704 3710 1:CAS:528:DC%2BD1cXht1OitrzE 10.1093/ndt/gfn321 18567695
45. F Zannad M Kessler P Lehert, et al. 2006 Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies Kidney Int 70 1318 1324 1:CAS:528: DC%2BD28Xpsl2qsLc%3D 10.1038/sj.ki.5001657 16871247 (Pubitemid 44435184)
46. F Zannad M Kessler JP Grunfeld C Thuilliez 2002 FOSIDIAL: a randomised placebo controlled trial of the effects of fosinopril on cardiovascular morbidity and mortality in haemodialysis patients. Study design and patients' baseline characteristics Fundam Clin Pharmacol 16 353 360 1:CAS:528: DC%2BD38Xptlejs74%3D 10.1046/j.1472-8206.2002.00127.x 12602460 (Pubitemid 35356945)
47. A Takahashi H Takase T Toriyama, et al. 2006 Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis-a randomized study Nephrol Dial Transplant 21 2507 2512 1:CAS:528:DC%2BD28XhtVWlt7%2FJ 10.1093/ndt/gfl293 16766543 (Pubitemid 44644524)
48. H Suzuki Y Kanno S Sugahara, et al. 2008 Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial Am J Kidney Dis 52 501 506 1:CAS:528:DC%2BD1cXhtFOrt7zI 10.1053/j.ajkd.2008.04.031 18653268
49. SW Han YW Won JH Yi HJ Kim 2007 No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients Nephrol Dial Transplant 22 1150 1155 1:CAS:528:DC%2BD2sXjslOgtbo%3D 10.1093/ndt/gfl752 17255126 (Pubitemid 46523431)
50. Y Matsumoto S Kageyama T Yakushigawa, et al. 2009 Long-term low-dose spironolactone therapy is safe in oligoanuric hemodialysis patients Cardiology 114 32 38 1:CAS:528:DC%2BD1MXptFGkurc%3D 10.1159/000210553 19342857 This prospective study investigated the effect on serum potassium levels from daily spironolactone in oligoanuric hemodialysis patients and found no clinical difference between baseline potassium levels and levels taken over 6 months of follow-up